Antisense-mediated modulation of splicing: Therapeutic implications for duchenne muscular dystrophy

  • Aartsma-Rus A
  • 42

    Readers

    Mendeley users who have this article in their library.
  • 55

    Citations

    Citations of this article.

Abstract

While disruption of alternative splicing underlies many diseases, modulation of splicing using antisense oligonucleotides (AONs) can have therapeutic implications. The most notable example is Duchenne muscular dystrophy (DMD), where antisense-mediated exon skipping can restore the open reading frame and allow the synthesis of partly functional dystrophin proteins instead of non-functional ones. This approach is currently tested in early phase clinical trials. In this review the development of the exon skipping approach in patient-derived cell cultures, animal models and patients is described and hurdles that have to be overcome to make this personalized medicine type approach widely applicable are discussed.

Author-supplied keywords

  • Antisense oligonucleotides
  • Clinical trials
  • Exon skipping
  • Neuromuscular disorders
  • Splicing
  • Therapy

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Annemieke Aartsma-Rus

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free